The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis
Open accessAbstract
Amphotericin B (AMB) remains the principal therapeutic choice for deep mycoses. However, its application is limited by toxicity and a route of administration requiring slow intravenous injection. An oral formulation of this drug is desirable to treat acute infections and provide prophylactic therapy for high-risk patients. Cochleates are a novel lipid-based delivery system that have the potential for oral administration of hydrophobic drugs. They are stable phospholipid-cation crystalline structures consisting of a spiral lipid bilayer sheet with no internal aqueous space. Cochleates containing AMB (CAMB) inhibit the growth of Candida albicans, and the in vivo therapeutic efficacy of CAMB administered orally was evaluated in a mouse model of systemic candidiasis. The results indicate that 100% of the mice treated at all CAMB doses, including a low dosage of 0.5 mg/kg of body weight/day, survived the experimental period (16 days). In contrast, 100% mortality was observed with untreated mice by day 12. The fungal tissue burden in kidneys and lungs was assessed in parallel, and a dose-dependent reduction in C. albicans from the kidneys was observed, with a maximum 3.5-log reduction in total cell counts at 2.5 mg/kg/day. However, complete clearance of the organism from the lungs, resulting in more than a 4-log reduction, was observed at the same dose. These results were comparable to a deoxycholate AMB formulation administered intraperitoneally at 2 mg/kg/day (P < 0.05). Overall, these data demonstrate that cochleates are an effective oral delivery system for AMB in a model of systemic candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Orally administered MAT2203 prevented death”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [119]
In the citing paper
“reduced tissue fungal burden in mice with invasive candidiasis [119,120]”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Beck‐Sagué, C. M., Jarvis, W. R., & System, N. N. I. S. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,013
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A. C., Bow, E. J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 623
Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles
Papahadjopoulos, D., Vail, W. J., Jacobson, K., & Poste, G. H. (1975) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(75)90299-0 · Cited by 542
Amphotericin B: current understanding of mechanisms of action
Brajtburg, J., Powderly, W. G., Kobayashi, G. S., & Medoff, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.183 · Cited by 503
Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients
Kauffman, C. A., Vazquez, J. A., Sobel, J. D., Gallis, H. A., McKinsey, D. S., Karchmer, A. W., Sugar, A. M., Sharkey, P. K., Wise, G. J., Mangi, R., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313583 · Cited by 483
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong‐Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 394
Research works printed but not linked: 1
- Zarif L. Segarra L. Jin T. Scolpino A. Hyra D. Perlin D. S. Graybill J. R. Mannino R. J. Oral and systemic delivery of AmB mediated by cochleates. AAPS PharmSci. 1 1999 S-453
Cited by
Sorted by citations
Items 101–150 of 150
The antifungal pipeline: the need is established. Are there new compounds?
Li, D., She, X., & Calderone, R. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa023 · Cited by 15
Wasan, K. M., Sivak, O., Bartlett, K. H., Wasan, E. K., & Gershkovich, P. (2014) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2014.954587 · Cited by 12
Nanocochleates: Revolutionizing lipid-based drug delivery with enhanced bioavailability, a review
Verekar, R. R., Dessai, S., Ayyanar, M., Nadaf, D. S., & Gurav, S. S. (2024) · Hybrid Advances · doi:10.1016/j.hybadv.2024.100215 · Cited by 11
Novel Drug Delivery Systems for Antifungal Compounds
Zia, Q., Farzuddin, M., Ansari, M. A., Alam, M., Ali, A., Ahmad, I., & Owais, M. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_20 · Cited by 11
Extreme Resilience in Cochleate Nanoparticles
Bozó, T., Brecska, R., Gróf, P., & Kellermayer, M. (2014) · Langmuir · doi:10.1021/la504428x · Cited by 11
Serrano, D. R., Lalatsa, A., & Dea‐Ayuela, M. A. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170719164318 · Cited by 11
Jain, K., Wadhwa, K., MALIK, M. L., Haque, S., Prieto, M. A., & Kaur, H. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf742 · Cited by 12
Nanotechnology and food safety
Rizvi, S. S. H., Moraru, C. I., Bouwmeester, H., Kampers, F. W. H., & Cheng, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-816011-4.00016-1 · Cited by 13
Formulation approaches in mitigating toxicity of orally administrated drugs
Kadiyala, I., & Tan, E. L. (2013) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2012.734516 · Cited by 8
Therapeutic Approaches for Combating Aspergillus Associated Infection
Chhillar, A. K., Punia, A., Choudhary, P., Sharma, N., Dahiya, S., & Gulia, P. (2022) · Current Drug Targets · doi:10.2174/1389450123666220623164548 · Cited by 8
Campo, S., Arseni, B., Rossi, S., D’Alessio, V., Lu, R., Ngoje, J., Ahl, P. L., Bonitz, S., Mannino, R. J., Mitri, D. D., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31817ba761 · Cited by 7
Therapeutic and Prophylactic Tools for Sporotrichosis: Current Strategies and Future Tendencies
Batista-Duharte, A., Pereira, S. A., Freitas, D. F. S., Fuentes, D. P., Gutierrez‐Galhardo, M. C., & Carlos, I. Z. (2015) · Springer eBooks · doi:10.1007/978-3-319-11912-0_9 · Cited by 6
Panda, P., De, M., & Basak, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89953-6.00006-4 · Cited by 6
Future Directions for Clinical Respiratory Fungal Research
Armstrong-James, D. P. H. (2021) · Mycopathologia · doi:10.1007/s11046-021-00579-5 · Cited by 6
Ji, C., Qiu, Z., Yang, Z., & Luo, P. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105347 · Cited by 5
Wasankar, S. R., Makeshwar, K. B., Deshmukh, A. D., & Burghate, R. M. (2012) · Research Journal of Pharmaceutical Dosage Forms and Technology · Cited by 5
Enriz, R. D., Suvire, F. D., Andújar, S. A., Alvarez, M. A., Vettorazzi, M., Dolab, J. G., & Rojas, S. M. (2017) · Current Organic Chemistry · doi:10.2174/1385272821666161222113628 · Cited by 5
The evaluation of herbal medicine efficacy on cutaneous Leishmaniasis
Seidi, Z. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.17463/rcm.2014.03.004 · Cited by 5
Engineered Commensal Bacteria as Delivery Systems of Anti-infective Mucosal Protectants
Magliani, W., Contt, S., Frazzi, R., Pozzi, G., Oggioni, M. R., & Polonelli, L. (2002) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2002.10648027 · Cited by 5
Exploring the promises and challenges of cochleates for drug delivery applications
Lee, J., Goo, Y. T., Shakhakarmi, K., Kang, M. J., & Lee, S. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00755-5 · Cited by 4
Cochleates as Nanoparticular Drug Carriers
Zarif, L. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860949074_0016 · Cited by 4
Seyedmousavi, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc295 · Cited by 4
Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03297-z · Cited by 5
Current Status of Drug Delivery Systems for Antifungal Drugs
Izumikawa, K., & Kohno, S. (2012) · Drug Delivery System · doi:10.2745/dds.27.93 · Cited by 3
Mohamed-Ahmed, A. H. A., Ginn, C., Croft, S. L., & Brocchini, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9164-4_16 · Cited by 3
Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients
Cabrera, N. L., George, I. A., Rauseo, A. M., Mazi, P. B., & Spec, A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000995 · Cited by 3
DRUG SOLUBILIZATION WITH ORGANIC SOLVENTS, SURFACTANTS AND LIPIDS
Stahl, P. H. (2003) · Elsevier eBooks · doi:10.1016/b978-012744481-9/50041-6 · Cited by 3
Nanomedicines in the Treatment of Fungal Diseases
Ahsan, A., Aslam, Q.-U.-A., & Prestidge, C. A. (2023) · Learning materials in biosciences · doi:10.1007/978-981-99-7626-3_8 · Cited by 2
New Antifungal Drugs: Discovery and Therapeutic Potential
Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 3
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 2
Application of Nanoparticles to Invasive Fungal Infections
Santos, S. R. D., Amaral, A. C., & Taborda, C. P. (2022) · Springer eBooks · doi:10.1007/978-981-16-9190-4_7 · Cited by 2
Insights in Antifungal Drug Discovery
Gay‐Andrieu, F., May, J. P., Li, D., Sun, N., Chen, H., Calderone, R., & Alex, D. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch24 · Cited by 2
Cushion, M. T., Kumar, P., Lu, R., Ashbaugh, A., Adeojo, L., Alfaro, R. M., Mannino, R. J., Tramont, E. C., & Kovacs, J. A. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa731 · Cited by 1
Drug Targets, Drug Effectors, and Drug Targeting and Delivery
Loiseau, P. M., & BARRATT, G. M. (2012) · Springer eBooks · doi:10.1007/978-3-7091-1125-3_16 · Cited by 1
Methods of Preparation of Drug Nanoparticles
Lee, J., Lim, G., & Chung, H. (2003) · Nanotechnologies for the Life Sciences · doi:10.1002/9783527610419.ntls0020 · Cited by 1
Brustoloni, Y. M. (2006) · Americanae (AECID Library) · Cited by 1
Kischkel, B. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2022.tde-13102022-121545 · Cited by 23
Yamamoto, Y. (2006) · Drug Delivery System · doi:10.2745/dds.21.529
Sistemik Fare Kandidoz Modelinde Antifungal Kombinasyonlarının Etkinliği
Artan, C., Koç, N., & Artan, M. O. (2010) · DergiPark (Istanbul University)
Mitra, S. (2011) · eScholarship@McGill (McGill) · doi:10.82308/19993
The Effect Of Combinations Of Antimycotics In A Mouse Model Of Systemic Candidiasis
Oğuzkaya-Artan, M., Koç, N., & Artan, C. (2009) · Balkan Medical Journal · doi:10.5174/tutfd.2009.02272.1
Amphotericin B incorporated in liquid crystals for lung fungal infection treatment
Chuealee, R. (2009) · PSU Knowledge Bank (Prince of Songkla University)
Aspergillus-Human Interactions: From the Environment to Clinical Significance
Thammahong, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98509
[Gas-chromatographic analysis of propylene oxide in the air and biological media].
Борисов, Б. М., Bylyko, T. M., Gal'ianova, I. A., Kaprova, N. M., & Martirova, T. A. (1990) · PubMed
Ruiz-Herrera, J. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1166452.627436
Santos, S. R. D. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2022.tde-22062023-154055
Recent Advances in the Management of Aspergillosis
Gupta, C., & Dar, S. A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_16
Evaluation of Antimicrobials Incorporated into Artificial Saliva: Analysis Against Candida albicans
Carneiro, C. A., Pontes, F. M. L., Neppelenbroek, K. H., França, R., & Porto, V. C. (2026) · Journal of Functional Biomaterials · doi:10.3390/jfb17020063
BindingDB (2020) · UC San Diego · doi:10.7270/q2028vb5
Metadata
- Authors
- Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S.
- Affiliations
- <!--label omitted: 1-->Public Health Research Institute, New York, New York, 10016,1 and
- <!--label omitted: 2-->BioDelivery Science Inc. UMDNJ, Newark, New Jersey 071032
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-09
- Volume
- 44
- Issue
- 9
- Pages
- 2356-2360
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC90069
- OpenAlex
- W2004315110
- Cited by
- 150
- References
- 44
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 5 · 2018: 3 · 2017: 10 · 2016: 2 · 2015: 3 · 2014: 6 · 2013: 7 · 2012: 4
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Allergy and Infectious Diseases (R43AI046040, R43-AI-46040)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- amphotericin B, cochleates, oral drug delivery, systemic candidiasis, Candida albicans, lipid-based drug delivery, antifungal therapy, mouse model
- MeSH terms
- Administration, Oral, Amphotericin B, Animals, Antifungal Agents, Candidiasis, Chemistry, Pharmaceutical, Delayed-Action Preparations, Disease Models, Animal, Drug Carriers, Female, Kidney, Lung, Mice, Inbred BALB C, Drug Delivery Systems, Treatment Outcome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
